Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor


Dr J.-C. Desfontis, Unité de Physiopathologie Animale et Pharmacologie Fonctionnelle, UPSP 5304, Ecole Nationale Vétérinaire de Nantes, BP 40706, 44307 Nantes Cedex 03, France. E-mail: desfontis@vet-nantes.fr


The objective of this study was to investigate renal function in clinically normal dogs receiving tepoxalin, a nonsteroidal inflammatory drug, either in association with or without an angiotensin-converting enzyme inhibitor (ACEI). Ten adult female Beagle dogs were used in the three phases of the study. The dogs were administered the drugs once daily for 7 days (experiment 1: placebo/tepoxalin/tepoxalin and benazepril; experiment 2: enalapril/tepoxalin and enalapril) or for 28 days (experiment 3: tepoxalin and benazepril together).

Renal function was assessed by measurement of glomerular filtration rate (GFR) by renal scintigraphy [(renal uptake of 99mTc-diethylenetriaminepentacetic acid (DTPA)] and plasma clearance of 99mTc-DTPA. Compared with the placebo group, renal uptake and plasma clearance of 99mTc-DTPA were not significantly modified after a 7-day period of treatment with tepoxalin or enalapril alone, tepoxalin and benazepril or tepoxalin and enalapril together. No significant change was obtained in GFR after a 28-day period of dosing with tepoxalin and benazepril together.

Therefore, it was concluded that tepoxalin did not alter renal function in healthy Beagle dogs receiving ACEI.